Wind data shows that as of January 13, 186 listed companies have received centralized research from institutions such as public offerings and securities companies, with a total of 220 times of research. Among them, the number of participating institutions in "popular" targets such as Aipeng Medical, Entropy Technology, and Chaojie Shares are all over 120. From the research content, the progress and layout of popular fields such as brain computer interfaces, commercial aerospace, and humanoid robots have become key topics of inquiry for institutions. The South China Morning Post recently published an article stating that UBS Group is optimistic about the prospects of the Chinese stock market in 2026, and global investors are seeking diversification from high valuation US stocks. China's huge economy and technological innovation capabilities make it an important choice. The head of UBS Global Markets China stated that the growth of corporate profits, policy support, improvement of innovation capabilities, and potential inflow of foreign capital will drive the development of the stock market, making it an important market for global capital diversification. The report also mentioned that in the past year, the Chinese stock market has outperformed the US stock market; As the US government attempts to influence the Federal Reserve, investors are turning to other markets, including China, and AI related companies may become a market focus due to their lower correlation. In addition, the daily trading volume of the Shanghai and Shenzhen stock exchanges recently reached a record high of 3.58 trillion yuan, with some indices consolidating around four-year highs. UBS strategist Meng Lei said that the surge in trading volume should not be interpreted as a signal of excessive speculation, as the speed of opening new stock accounts in 2025 is moderate, and the proportion of leveraged trading as a key stock market indicator of market value remains low. (New Society)